



Alliance Public Study Result Summary

Alliance A091103

What this study is about

A study that determined how well a drug worked in treating patients with advanced angiosarcoma that could not be removed by surgery.

The full title of this study is: Phase II study of the angiotensin-1 and -2 peptibody AMG 386 for the treatment of angiosarcoma

Why the study was done

Angiosarcoma is a rare cancer that may grow in a way that it becomes not possible to remove surgically. The tumor cells are characterized by upregulation of the angiotensin system (Tie2 and Ang 2). Trebananib (also known as AMG 386) is a novel drug that blocks this system.

This study was done to see if using trebananib could lead to shrinkage of angiosarcoma in people.

Study results

These results are for people with angiosarcoma that has spread and could not be removed by surgery.

The study found that no patients had significant shrinkage of the sarcoma and most patients had tumor growth by 8 weeks, although 4 patients had no significant growth for 4-5 months.


The most common serious side effects included blood clots and anemia, although these occurred only in 3 patients.

What the results mean

This means that trebananib has very little activity in patients with angiosarcoma.

How the study worked

Here's a picture that explains how patients were placed into this study.



When did the study start and end? The study started in July 2012. All patients were enrolled by January 2014.

How many patients joined? 16 patients were enrolled in this study.

Talk to your doctor if you want more information about this study.

Scientific publications about this study

This summary includes information in the following article:

- **Alliance A091103: A Phase II Study of the Angiotensin 1 and 2 Peptibody Trebananib for the Treatment of Angiosarcoma.** D' Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, Luke JJ, Hartley EW, Antonescu CR, Tap WD, Schwartz GK.



Alliance Public Study Result Summary Alliance A091103

Cancer Chemother Pharmacol. 2015 Mar;75(3):629-38. doi: 10.1007/s00280-015-2689-8.
Epub 2015 Feb 12.

To learn about this trial, visit the ClinicalTrials.gov website at
<https://clinicaltrials.gov/ct2/show/NCT01623869>

This study was sponsored by the Alliance for Clinical Trials in Oncology – a national clinical trial network group that runs large cancer clinical trials. The Alliance is supported by the National Cancer Institute (NCI) and brings researchers together to develop better treatments for cancers. More information about the Alliance is at <http://www.allianceforclinicaltrialsinoncology.org>.

*This summary lists what is known about this research study as of February 2015.
New Information may be available.*

We thank the people who joined this study and made it possible.

We do research to try to learn the best ways to help patients.

The people who joined this study helped us to do that.

Thank you for your interest in learning more about cancer research advances.